You are here
Unmet Needs and Rationale for Combination Therapies for Diabetes Specialists
for Diabetes Specialists
In this course, you will learn about the rationale for adding a glucagon-like peptide-1 (GLP-1) receptor agonist to basal insulin therapy. The complementary effects of basal insulin–GLP-1 receptor agonist combination therapy will be discussed in terms of glycaemic control, change in body weight, and risk of hypoglycaemia. Sign up to the E-Alert to be updated on all new publications.
Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk